ARCH Venture Partners invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH Ventures enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. For more information visit www.archventure.com.
Bain Capital Ventures is the Boston-based venture capital arm of Bain Capital, whose affiliates manage over $50 billion of assets. Founded in 1984, Bain Capital and its affiliates have invested in over 230 companies with such notable successes as Doubleclick, Gartner Group and Staples. Bain’s history of investing in early stage companies also dates back to 1984, having made over 120 venture-stage investments since inception. In 2001, Bain Capital Ventures was formed as a separate arm of Bain Capital to focus exclusively on seed through late-stage growth investments in software, hardware, information, healthcare, and technology-driven business services companies. For more information visit www.baincapital.com.
A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2014, revenues reached €1.698 billion with 88% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. For more information visit: www.biomerieux.com.
Cormorant Asset Management
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio companies include: Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), Agios (NASDAQ: AGIO), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH), and Morphotek (acquired by Eisai). Additional notable portfolio companies include: Affinnova, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics. For more information, please visit www.flagshipventures.com.
Founded in 2007, Quanterix has developed an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today.
The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more.
Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).
Recent Webcast Presentations
Quanterix at JP Morgan Healthcare Conference 2016
January 12, 2016
Quanterix at Stifel 2015 Healthcare Conference (Replay)
November 19, 2015
Recent Media Coverage
Quanterix In The News
19 Oct 2016
October 7, 2016
18 Oct 2016Read More
Lexington, Mass. – October 18, 2016—Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, has been named the “Late Stage Leader”Buzz of BIO winner. As a winner of this award – which recognizes innovative companies that have raised more than $25 million as of July 1, 2016 – Quanterix will also be presenting at the 2016 BIO Investor Forum, taking place October 18-19 in San Francisco.
14 Oct 2016
Read the article at www.centerwatch.com.
11 Oct 2016
Read the article at www.smartceo.com.
30 Sep 2016
Read the article at www.sportsnaut.com.
Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition14 Oct 2016
Serum neurofilament light protein as a marker for diffuse axonal injury - results from a case series study.03 Oct 2016
Rapid and ultrasensitive detection of botulinum neurotoxin serotype A1 in human serum and urine using single-molecule array method12 Sep 2016
Investor Contact Information
Tel: +1 (617) 301-9400